vs
Side-by-side financial comparison of NU SKIN ENTERPRISES, INC. (NUS) and Organogenesis Holdings Inc. (ORGO). Click either name above to swap in a different company.
NU SKIN ENTERPRISES, INC. is the larger business by last-quarter revenue ($320.6M vs $37.2M, roughly 8.6× Organogenesis Holdings Inc.). On growth, NU SKIN ENTERPRISES, INC. posted the faster year-over-year revenue change (-12.0% vs -57.1%). Over the past eight quarters, NU SKIN ENTERPRISES, INC.'s revenue compounded faster (-14.5% CAGR vs -46.5%).
Nu Skin Enterprises, Inc. is an American multilevel marketing company that develops and sells personal care products and dietary and nutritional supplements. Under the Nu Skin and Pharmanex brands, the company sells its products in 54 markets through a network of approximately 1.2 million independent distributors.
Organogenesis Holdings Inc. is a leading regenerative medicine firm specializing in developing and manufacturing advanced therapeutic products for wound care, surgical repair, sports medicine, and dermatology. It serves healthcare providers and patients primarily in the U.S. and select international markets, offering clinically validated solutions for unmet medical needs.
NUS vs ORGO — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $320.6M | $37.2M |
| Net Profit | $1.8M | — |
| Gross Margin | 66.9% | 30.8% |
| Operating Margin | 34.4% | -185.1% |
| Net Margin | 0.6% | — |
| Revenue YoY | -12.0% | -57.1% |
| Net Profit YoY | — | — |
| EPS (diluted) | $0.04 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $320.6M | $37.2M | ||
| Q4 25 | $370.3M | $225.6M | ||
| Q3 25 | $364.2M | $150.9M | ||
| Q2 25 | $386.1M | $101.0M | ||
| Q1 25 | $364.5M | $86.7M | ||
| Q4 24 | $445.6M | $126.7M | ||
| Q3 24 | $430.1M | $115.2M | ||
| Q2 24 | $439.1M | $130.2M |
| Q1 26 | $1.8M | — | ||
| Q4 25 | $14.5M | $43.7M | ||
| Q3 25 | $17.1M | $21.6M | ||
| Q2 25 | $21.1M | $-9.4M | ||
| Q1 25 | $107.5M | $-18.8M | ||
| Q4 24 | $-36.1M | $7.7M | ||
| Q3 24 | $8.3M | $12.3M | ||
| Q2 24 | $-118.3M | $-17.0M |
| Q1 26 | 66.9% | 30.8% | ||
| Q4 25 | 70.7% | — | ||
| Q3 25 | 70.5% | — | ||
| Q2 25 | 68.8% | — | ||
| Q1 25 | 67.8% | 72.6% | ||
| Q4 24 | 62.7% | 75.5% | ||
| Q3 24 | 70.1% | 76.7% | ||
| Q2 24 | 70.0% | 77.6% |
| Q1 26 | 34.4% | -185.1% | ||
| Q4 25 | 6.3% | 28.1% | ||
| Q3 25 | 5.9% | 13.7% | ||
| Q2 25 | 8.0% | -12.5% | ||
| Q1 25 | -2.7% | -30.9% | ||
| Q4 24 | -11.9% | 8.1% | ||
| Q3 24 | 4.2% | 5.4% | ||
| Q2 24 | -28.6% | -10.7% |
| Q1 26 | 0.6% | — | ||
| Q4 25 | 3.9% | 19.4% | ||
| Q3 25 | 4.7% | 14.3% | ||
| Q2 25 | 5.5% | -9.3% | ||
| Q1 25 | 29.5% | -21.7% | ||
| Q4 24 | -8.1% | 6.1% | ||
| Q3 24 | 1.9% | 10.7% | ||
| Q2 24 | -26.9% | -13.1% |
| Q1 26 | $0.04 | — | ||
| Q4 25 | $0.27 | $0.31 | ||
| Q3 25 | $0.34 | $0.11 | ||
| Q2 25 | $0.43 | $-0.10 | ||
| Q1 25 | $2.14 | $-0.17 | ||
| Q4 24 | $-0.73 | $0.05 | ||
| Q3 24 | $0.17 | $0.09 | ||
| Q2 24 | $-2.38 | $-0.13 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $198.7M | $91.4M |
| Total DebtLower is stronger | $223.6M | — |
| Stockholders' EquityBook value | $794.1M | — |
| Total Assets | $1.4B | $520.0M |
| Debt / EquityLower = less leverage | 0.28× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $198.7M | $91.4M | ||
| Q4 25 | $239.8M | $93.7M | ||
| Q3 25 | $253.0M | $63.7M | ||
| Q2 25 | $265.4M | $73.1M | ||
| Q1 25 | $213.6M | $110.0M | ||
| Q4 24 | $198.0M | $135.6M | ||
| Q3 24 | $237.8M | $94.3M | ||
| Q2 24 | $232.9M | $89.9M |
| Q1 26 | $223.6M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $62.3M | ||
| Q2 24 | — | $63.8M |
| Q1 26 | $794.1M | — | ||
| Q4 25 | $805.2M | $300.1M | ||
| Q3 25 | $799.8M | $255.1M | ||
| Q2 25 | $787.8M | $233.2M | ||
| Q1 25 | $754.0M | $242.9M | ||
| Q4 24 | $651.5M | $262.9M | ||
| Q3 24 | $706.9M | $278.5M | ||
| Q2 24 | $686.2M | $263.5M |
| Q1 26 | $1.4B | $520.0M | ||
| Q4 25 | $1.4B | $598.7M | ||
| Q3 25 | $1.4B | $509.8M | ||
| Q2 25 | $1.4B | $461.1M | ||
| Q1 25 | $1.4B | $467.4M | ||
| Q4 24 | $1.5B | $497.9M | ||
| Q3 24 | $1.6B | $446.3M | ||
| Q2 24 | $1.6B | $443.2M |
| Q1 26 | 0.28× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.22× | ||
| Q2 24 | — | 0.24× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
